Recombinant bovine growth hormone treatment of tilapia: Growth response, metabolic clearance, receptor binding and immunoglobulin production

Thomas A. Leedom, Katsuhisa Uchida, Takashi Yada, N. Harold Richman, John C. Byatt, Robert J Collier, Tetsuya Hirano, E. Gordon Grau

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Experiments were performed to examine the growth-promoting effects of recombinant bovine growth hormone (rbGH) in the euryhaline tilapia (Oreochromis mossambicus). A radioreceptor assay using a crude membrane preparation of tilapia liver revealed that rbGH was about 100-fold less potent than native tilapia GH (tGH) in displacing 125I-labeled tGH. Bovine prolactin (bPRL) was equipotent to bovine GH indicating that the GH receptor of tilapia does not distinguish mammalian GH from mammalian PRL. When juvenile tilapia, weighing 1 g, were maintained at 28°C and received intraperitoneal injection of rbGH at doses of 0.1, 1 or 10 μg/g weekly for 8 weeks, no significant effect on growth was observed. A second experiment examined weekly doses ranging from 1 to 50 μg/g for 16 weeks, using 1 g fish maintained at 23°C. rbGH (50 μg/g) significantly increased growth after 14 and 16 weeks, although the growth rate was significantly less than those held at 28°C. More pronounced growth-promoting effects were observed, however, when fish weighing 5 g and held at 29°C were injected with rbGH at doses of 100 and 1000 μg/g once a week for 4 weeks. A single injection of a sustained-release formulation of rbGH (Posilac®, 100 and 1000 μg/g) also elicited growth-promoting effects in fish weighing 4 g and kept at 29°C. Treatment with rbGH, Posilac® or bovine serum albumin (BSA) elicited significant increases in plasma levels of immunoglobulin (IgM) in a dose-dependent manner. By contrast, there was no change in plasma levels of lysozyme activity in rbGH- or Posilac®-injected fish compared with controls. An uptake and clearance study confirmed a slower decline in circulating levels of rbGH following Posilac® injection compared with rbGH in saline. There was no change in plasma concentration of tGH after rbGH treatment, indicating that GH secretion from the tilapia pituitary was unaffected by high plasma levels of rbGH. The relative refractoriness of juvenile tilapia to growth-promoting effects of rbGH compared with that of other species may be due to the specific nature of the tGH receptor in recognizing the homologous hormone.

Original languageEnglish (US)
Pages (from-to)359-380
Number of pages22
JournalAquaculture
Volume207
Issue number3-4
DOIs
StatePublished - May 24 2002

Fingerprint

Tilapia (Cichlidae)
growth response
somatotropin
immunoglobulins
hormone
receptors
tilapia (common name)
dosage
fish
bovine
plasma
injection
Oreochromis mossambicus
cattle
bovine serum albumin
intraperitoneal injection
prolactin
lysozyme

Keywords

  • Plasma growth hormone
  • Plasma immunoglobulin
  • Plasma lysozyme
  • Posilac
  • Receptor assay
  • Tilapia

ASJC Scopus subject areas

  • Aquatic Science

Cite this

Recombinant bovine growth hormone treatment of tilapia : Growth response, metabolic clearance, receptor binding and immunoglobulin production. / Leedom, Thomas A.; Uchida, Katsuhisa; Yada, Takashi; Richman, N. Harold; Byatt, John C.; Collier, Robert J; Hirano, Tetsuya; Grau, E. Gordon.

In: Aquaculture, Vol. 207, No. 3-4, 24.05.2002, p. 359-380.

Research output: Contribution to journalArticle

Leedom, Thomas A. ; Uchida, Katsuhisa ; Yada, Takashi ; Richman, N. Harold ; Byatt, John C. ; Collier, Robert J ; Hirano, Tetsuya ; Grau, E. Gordon. / Recombinant bovine growth hormone treatment of tilapia : Growth response, metabolic clearance, receptor binding and immunoglobulin production. In: Aquaculture. 2002 ; Vol. 207, No. 3-4. pp. 359-380.
@article{c72adc625a1b47ccb45bba7c0fad235f,
title = "Recombinant bovine growth hormone treatment of tilapia: Growth response, metabolic clearance, receptor binding and immunoglobulin production",
abstract = "Experiments were performed to examine the growth-promoting effects of recombinant bovine growth hormone (rbGH) in the euryhaline tilapia (Oreochromis mossambicus). A radioreceptor assay using a crude membrane preparation of tilapia liver revealed that rbGH was about 100-fold less potent than native tilapia GH (tGH) in displacing 125I-labeled tGH. Bovine prolactin (bPRL) was equipotent to bovine GH indicating that the GH receptor of tilapia does not distinguish mammalian GH from mammalian PRL. When juvenile tilapia, weighing 1 g, were maintained at 28°C and received intraperitoneal injection of rbGH at doses of 0.1, 1 or 10 μg/g weekly for 8 weeks, no significant effect on growth was observed. A second experiment examined weekly doses ranging from 1 to 50 μg/g for 16 weeks, using 1 g fish maintained at 23°C. rbGH (50 μg/g) significantly increased growth after 14 and 16 weeks, although the growth rate was significantly less than those held at 28°C. More pronounced growth-promoting effects were observed, however, when fish weighing 5 g and held at 29°C were injected with rbGH at doses of 100 and 1000 μg/g once a week for 4 weeks. A single injection of a sustained-release formulation of rbGH (Posilac{\circledR}, 100 and 1000 μg/g) also elicited growth-promoting effects in fish weighing 4 g and kept at 29°C. Treatment with rbGH, Posilac{\circledR} or bovine serum albumin (BSA) elicited significant increases in plasma levels of immunoglobulin (IgM) in a dose-dependent manner. By contrast, there was no change in plasma levels of lysozyme activity in rbGH- or Posilac{\circledR}-injected fish compared with controls. An uptake and clearance study confirmed a slower decline in circulating levels of rbGH following Posilac{\circledR} injection compared with rbGH in saline. There was no change in plasma concentration of tGH after rbGH treatment, indicating that GH secretion from the tilapia pituitary was unaffected by high plasma levels of rbGH. The relative refractoriness of juvenile tilapia to growth-promoting effects of rbGH compared with that of other species may be due to the specific nature of the tGH receptor in recognizing the homologous hormone.",
keywords = "Plasma growth hormone, Plasma immunoglobulin, Plasma lysozyme, Posilac, Receptor assay, Tilapia",
author = "Leedom, {Thomas A.} and Katsuhisa Uchida and Takashi Yada and Richman, {N. Harold} and Byatt, {John C.} and Collier, {Robert J} and Tetsuya Hirano and Grau, {E. Gordon}",
year = "2002",
month = "5",
day = "24",
doi = "10.1016/S0044-8486(01)00767-0",
language = "English (US)",
volume = "207",
pages = "359--380",
journal = "Aquaculture",
issn = "0044-8486",
publisher = "Elsevier",
number = "3-4",

}

TY - JOUR

T1 - Recombinant bovine growth hormone treatment of tilapia

T2 - Growth response, metabolic clearance, receptor binding and immunoglobulin production

AU - Leedom, Thomas A.

AU - Uchida, Katsuhisa

AU - Yada, Takashi

AU - Richman, N. Harold

AU - Byatt, John C.

AU - Collier, Robert J

AU - Hirano, Tetsuya

AU - Grau, E. Gordon

PY - 2002/5/24

Y1 - 2002/5/24

N2 - Experiments were performed to examine the growth-promoting effects of recombinant bovine growth hormone (rbGH) in the euryhaline tilapia (Oreochromis mossambicus). A radioreceptor assay using a crude membrane preparation of tilapia liver revealed that rbGH was about 100-fold less potent than native tilapia GH (tGH) in displacing 125I-labeled tGH. Bovine prolactin (bPRL) was equipotent to bovine GH indicating that the GH receptor of tilapia does not distinguish mammalian GH from mammalian PRL. When juvenile tilapia, weighing 1 g, were maintained at 28°C and received intraperitoneal injection of rbGH at doses of 0.1, 1 or 10 μg/g weekly for 8 weeks, no significant effect on growth was observed. A second experiment examined weekly doses ranging from 1 to 50 μg/g for 16 weeks, using 1 g fish maintained at 23°C. rbGH (50 μg/g) significantly increased growth after 14 and 16 weeks, although the growth rate was significantly less than those held at 28°C. More pronounced growth-promoting effects were observed, however, when fish weighing 5 g and held at 29°C were injected with rbGH at doses of 100 and 1000 μg/g once a week for 4 weeks. A single injection of a sustained-release formulation of rbGH (Posilac®, 100 and 1000 μg/g) also elicited growth-promoting effects in fish weighing 4 g and kept at 29°C. Treatment with rbGH, Posilac® or bovine serum albumin (BSA) elicited significant increases in plasma levels of immunoglobulin (IgM) in a dose-dependent manner. By contrast, there was no change in plasma levels of lysozyme activity in rbGH- or Posilac®-injected fish compared with controls. An uptake and clearance study confirmed a slower decline in circulating levels of rbGH following Posilac® injection compared with rbGH in saline. There was no change in plasma concentration of tGH after rbGH treatment, indicating that GH secretion from the tilapia pituitary was unaffected by high plasma levels of rbGH. The relative refractoriness of juvenile tilapia to growth-promoting effects of rbGH compared with that of other species may be due to the specific nature of the tGH receptor in recognizing the homologous hormone.

AB - Experiments were performed to examine the growth-promoting effects of recombinant bovine growth hormone (rbGH) in the euryhaline tilapia (Oreochromis mossambicus). A radioreceptor assay using a crude membrane preparation of tilapia liver revealed that rbGH was about 100-fold less potent than native tilapia GH (tGH) in displacing 125I-labeled tGH. Bovine prolactin (bPRL) was equipotent to bovine GH indicating that the GH receptor of tilapia does not distinguish mammalian GH from mammalian PRL. When juvenile tilapia, weighing 1 g, were maintained at 28°C and received intraperitoneal injection of rbGH at doses of 0.1, 1 or 10 μg/g weekly for 8 weeks, no significant effect on growth was observed. A second experiment examined weekly doses ranging from 1 to 50 μg/g for 16 weeks, using 1 g fish maintained at 23°C. rbGH (50 μg/g) significantly increased growth after 14 and 16 weeks, although the growth rate was significantly less than those held at 28°C. More pronounced growth-promoting effects were observed, however, when fish weighing 5 g and held at 29°C were injected with rbGH at doses of 100 and 1000 μg/g once a week for 4 weeks. A single injection of a sustained-release formulation of rbGH (Posilac®, 100 and 1000 μg/g) also elicited growth-promoting effects in fish weighing 4 g and kept at 29°C. Treatment with rbGH, Posilac® or bovine serum albumin (BSA) elicited significant increases in plasma levels of immunoglobulin (IgM) in a dose-dependent manner. By contrast, there was no change in plasma levels of lysozyme activity in rbGH- or Posilac®-injected fish compared with controls. An uptake and clearance study confirmed a slower decline in circulating levels of rbGH following Posilac® injection compared with rbGH in saline. There was no change in plasma concentration of tGH after rbGH treatment, indicating that GH secretion from the tilapia pituitary was unaffected by high plasma levels of rbGH. The relative refractoriness of juvenile tilapia to growth-promoting effects of rbGH compared with that of other species may be due to the specific nature of the tGH receptor in recognizing the homologous hormone.

KW - Plasma growth hormone

KW - Plasma immunoglobulin

KW - Plasma lysozyme

KW - Posilac

KW - Receptor assay

KW - Tilapia

UR - http://www.scopus.com/inward/record.url?scp=0037166009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037166009&partnerID=8YFLogxK

U2 - 10.1016/S0044-8486(01)00767-0

DO - 10.1016/S0044-8486(01)00767-0

M3 - Article

AN - SCOPUS:0037166009

VL - 207

SP - 359

EP - 380

JO - Aquaculture

JF - Aquaculture

SN - 0044-8486

IS - 3-4

ER -